Literature DB >> 20368743

Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors.

Annika Schaefer1, Carsten Stephan, Jonas Busch, George M Yousef, Klaus Jung.   

Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs that have an important role in the regulation of carcinogenic pathways. The observations that miRNAs are differentially expressed in tumor versus corresponding normal tissue, and that they regulate important breakpoints during carcinogenesis, are of interest for urologic oncologists. As biomarkers, they might be helpful tools for diagnostic, prognostic and monitoring purposes. Furthermore, miRNAs might be potential targets for novel therapeutic strategies, especially in patients with tumor subtypes that do not respond to currently available therapies. In this Review, we will focus on the current proceedings of miRNA research in urologic tumors. In the past decade, the number of published articles related to miRNAs in urologic oncology has increased, highlighting the ongoing importance of miRNAs in this field. Current studies support the hypothesis that miRNA will gain influence in clinical practice. Here, therefore, we illustrate the current knowledge of miRNA function in urologic tumors and draw the attention of urologists to the future opportunities and challenges of this research field.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368743     DOI: 10.1038/nrurol.2010.45

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  111 in total

1.  Long, abundantly expressed non-coding transcripts are altered in cancer.

Authors:  Damon S Perez; Tiffany R Hoage; Jay R Pritchett; Allison L Ducharme-Smith; Meredith L Halling; Sree C Ganapathiraju; Paul S Streng; David I Smith
Journal:  Hum Mol Genet       Date:  2007-11-15       Impact factor: 6.150

2.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

3.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

4.  MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL.

Authors:  Qiang Lu; Chao Lu; Guo-Ping Zhou; Wei Zhang; Hang Xiao; Xin-Ru Wang
Journal:  Urol Oncol       Date:  2009-09-19       Impact factor: 3.498

5.  Distinct microRNA alterations characterize high- and low-grade bladder cancer.

Authors:  James W F Catto; Saiful Miah; Helen C Owen; Helen Bryant; Katie Myers; Ewa Dudziec; Stéphane Larré; Marta Milo; Ishtiaq Rehman; Derek J Rosario; Erica Di Martino; Margaret A Knowles; Mark Meuth; Adrian L Harris; Freddie C Hamdy
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

6.  miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Aamir Ahmad; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

7.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

8.  Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.

Authors:  Yoshimasa Saito; Jeffrey M Friedman; Yoshitomo Chihara; Gerda Egger; Jody C Chuang; Gangning Liang
Journal:  Biochem Biophys Res Commun       Date:  2008-12-29       Impact factor: 3.322

9.  A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference.

Authors:  Yanjie Lu; Jiening Xiao; Huixian Lin; Yunlong Bai; Xiaobin Luo; Zhiguo Wang; Baofeng Yang
Journal:  Nucleic Acids Res       Date:  2009-01-09       Impact factor: 16.971

10.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  48 in total

1.  Suitable reference genes for relative quantification of miRNA expression in prostate cancer.

Authors:  Annika Schaefer; Monika Jung; Kurt Miller; Michael Lein; Glen Kristiansen; Andreas Erbersdobler; Klaus Jung
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

2.  A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Authors:  L A Selth; R Das; S L Townley; I Coutinho; A R Hanson; M M Centenera; N Stylianou; K Sweeney; C Soekmadji; L Jovanovic; C C Nelson; A Zoubeidi; L M Butler; G J Goodall; B G Hollier; P A Gregory; W D Tilley
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

3.  MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.

Authors:  Xiao-hui Ling; Zhao-dong Han; Dan Xia; Hui-chan He; Fu-neng Jiang; Zhuo-yuan Lin; Xin Fu; Ye-han Deng; Qi-shan Dai; Chao Cai; Jia-hong Chen; Yu-xiang Liang; Wei-de Zhong; Chin-lee Wu
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

Review 4.  microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles.

Authors:  Kirti Bhatt; Qing-Sheng Mi; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

Review 5.  Nanoways to overcome docetaxel resistance in prostate cancer.

Authors:  Aditya Ganju; Murali M Yallapu; Sheema Khan; Stephen W Behrman; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Resist Updat       Date:  2014-04-05       Impact factor: 18.500

6.  TGF-beta induced RBL2 expression in renal cancer cells by down-regulating miR-93.

Authors:  J Shi; Y Zhuang; X K Liu; Y X Zhang; Y Zhang
Journal:  Clin Transl Oncol       Date:  2014-09-03       Impact factor: 3.405

7.  Oncogenic microRNA-142-3p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma.

Authors:  Yifan Li; Duqun Chen; L U Jin; Jiaju Liu; Yuchi Li; Zhengming Su; Zhengyu Qi; Min Shi; Zhimao Jiang; Shangqi Yang; Yaoting Gui; Xiangming Mao; Xionghui Wu; Yongqing Lai
Journal:  Oncol Lett       Date:  2015-12-10       Impact factor: 2.967

8.  miR-205 regulates basement membrane deposition in human prostate: implications for cancer development.

Authors:  P Gandellini; V Profumo; A Casamichele; N Fenderico; S Borrelli; G Petrovich; G Santilli; M Callari; M Colecchia; S Pozzi; M De Cesare; M Folini; R Valdagni; R Mantovani; N Zaffaroni
Journal:  Cell Death Differ       Date:  2012-05-04       Impact factor: 15.828

Review 9.  The role of microRNA in castration-resistant prostate cancer.

Authors:  William Thieu; Derya Tilki; Ralph de Vere White; Christopher P Evans
Journal:  Urol Oncol       Date:  2014-07       Impact factor: 3.498

10.  Tumor suppressive miR-509-5p contributes to cell migration, proliferation and antiapoptosis in renal cell carcinoma.

Authors:  W-B Zhang; Z-Q Pan; Q-S Yang; X-M Zheng
Journal:  Ir J Med Sci       Date:  2013-04-26       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.